A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice

Neuroscience

Volumn 157, Issue 1, 2008, Pages 95-104

  Gandal, M J ^a,b   Ehrlichman, R S ^a   Rudnick, N D ^a   Siegel, S J ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

animal model; chemotherapy; cognitive impairment; event related potentials; post traumatic stress disorder; sensory gating

Indexed keywords

FLUOROURACIL; METHOTREXATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY STIMULATION; CANCER CHEMOTHERAPY; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; EVENT RELATED POTENTIAL; FEAR; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECOGNITION; TASK PERFORMANCE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AUDITORY PERCEPTION; COGNITION DISORDERS; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGY; EVOKED POTENTIALS; EVOKED POTENTIALS, AUDITORY; FEAR; FLUOROURACIL; MALE; METHOTREXATE; MICE; MICE, INBRED C57BL; NEUROTOXICITY SYNDROMES; RECOGNITION (PSYCHOLOGY);

EID: 54549103147     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.08.060     Document Type: Article

References (49)

1. Adler L.E., Hoffer L.D., Wiser A., and Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150 (1993) 1856-1861
2. Ahles T.A., and Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev 7 (2007) 192-201
3. Amir M., and Ramati A. Post-traumatic symptoms, emotional distress and quality of life in long-term survivors of breast cancer: a preliminary research. J Anxiety Disord 16 (2002) 195-206
4. Arciniegas D.B., and Topkoff J.L. Applications of the P50 evoked response to the evaluation of cognitive impairments after traumatic brain injury. Phys Med Rehabil Clin North Am 15 (2004) 177-203 viii
5. Braff D.L., and Light G.A. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl) 174 (2004) 75-85
6. Carpenter G.A., and Grossberg S. Normal and amnesic learning, recognition and memory by a neural model of cortico-hippocampal interactions. Trends Neurosci 16 (1993) 131-137
7. Connolly P.M., Maxwell C., Liang Y., Kahn J.B., Kanes S.J., Abel T., Gur R.E., Turetsky B.I., and Siegel S.J. The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem Res 29 (2004) 1179-1188
8. Connolly P.M., Maxwell C.R., Kanes S.J., Abel T., Liang Y., Tokarczyk J., Bilker W.B., Turetsky B.I., Gur R.E., and Siegel S.J. Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains. Brain Res 992 (2003) 85-95
9. Davies M.F., Tsui J.Y., Flannery J.A., Li X., DeLorey T.M., and Hoffman B.B. Augmentation of the noradrenergic system in alpha-2 adrenergic receptor deficient mice: anatomical changes associated with enhanced fear memory. Brain Res 986 (2003) 157-165
10. de Bruin N.M., Ellenbroek B.A., Cools A.R., Coenen A.M., and van Luijtelaar E.L. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology (Berl) 142 (1999) 9-17
11. Dietrich J., Han R., Yang M., Mayer-Proschel M., and Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5 (2006) 22
12. Ellenbroek B.A. Pre-attentive processing and schizophrenia: animal studies. Psychopharmacology (Berl) 174 (2004) 65-74
13. Fein G., Biggins C., and MacKay S. Cocaine abusers have reduced auditory P50 amplitude and suppression compared to both normal controls and alcoholics. Biol Psychiatry 39 (1996) 955-965
14. Gillette G.M., Skinner R.D., Rasco L.M., Fielstein E.M., Davis D.H., Pawelak J.E., Freeman T.W., Karson C.N., Boop F.A., and Garcia-Rill E. Combat veterans with posttraumatic stress disorder exhibit decreased habituation of the P1 midlatency auditory evoked potential. Life Sci 61 (1997) 1421-1434
15. Hakamata Y., Matsuoka Y., Inagaki M., Nagamine M., Hara E., Imoto S., Murakami K., Kim Y., and Uchitomi Y. Structure of orbitofrontal cortex and its longitudinal course in cancer-related post-traumatic stress disorder. Neurosci Res 59 (2007) 383-389
16. Jessen F., Kucharski C., Fries T., Papassotiropoulos A., Hoenig K., Maier W., and Heun R. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. Am J Psychiatry 158 (2001) 1319-1321
17. Kamm Y.J., Peters G.J., Hull W.E., Punt C.J., and Heerschap A. Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. Br J Cancer 89 (2003) 754-762
18. Karl A., Malta L.S., and Maercker A. Meta-analytic review of event-related potential studies in post-traumatic stress disorder. Biol Psychol 71 (2006) 123-147
19. Kreukels B.P., Schagen S.B., Ridderinkhof K.R., Boogerd W., Hamburger H.L., and van Dam F.S. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 94 (2005) 53-61
20. Labossiere E., and Glickstein M.E. Histological processing for the neural sciences (1976), Thomas, Springfield, IL
21. Lee G.D., Longo D.L., Wang Y., Rifkind J.M., Abdul-Raman L., Mamczarz J.A., Duffy K.B., Spangler E.L., Taub D.D., Mattson M.P., and Ingram D.K. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res 12 (2006) 198-205
22. Lobo E.D., and Balthasar J.P. Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. J Pharm Sci 92 (2003) 1654-1664
23. Maxwell C.R., Ehrlichman R.S., Liang Y., Gettes D.R., Evans D.L., Kanes S.J., Abel T., Karp J., and Siegel S.J. Corticosterone modulates auditory gating in mouse. Neuropsychopharmacology 31 (2006) 897-903
24. Maxwell C.R., Ehrlichman R.S., Liang Y., Trief D., Kanes S.J., Karp J., and Siegel S.J. Ketamine produces lasting disruptions in encoding of sensory stimuli. J Pharmacol Exp Ther 316 (2006) 315-324
25. Maxwell C.R., Kanes S.J., Abel T., and Siegel S.J. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129 (2004) 101-107
26. Maxwell C.R., Liang Y., Weightman B.D., Kanes S.J., Abel T., Gur R.E., Turetsky B.I., Bilker W.B., Lenox R.H., and Siegel S.J. Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology 29 (2004) 739-746
27. McFarlane A.C., Weber D.L., and Clark C.R. Abnormal stimulus processing in posttraumatic stress disorder. Biol Psychiatry 34 (1993) 311-320
28. Metzger K.L., Maxwell C.R., Liang Y., and Siegel S.J. Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol Psychiatry 61 (2006) 23-30
29. Metzger L.J., Orr S.P., Lasko N.B., and Pitman R.K. Auditory event-related potentials to tone stimuli in combat-related posttraumatic stress disorder. Biol Psychiatry 42 (1997) 1006-1015
30. Mueller D., Porter J.T., and Quirk G.J. Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. J Neurosci 28 (2008) 369-375
31. Okuda S., Roozendaal B., and McGaugh J.L. Glucocorticoid effects on object recognition memory require training-associated emotional arousal. Proc Natl Acad Sci U S A 101 (2004) 853-858
32. Parageorgiou C., Dardoufas C., Kouloulias V., Ventouras E., Uzunoglu N., Vlahos L., Rambavilas A., and Christodoulou G. Psychophysiological evaluation of short-term neurotoxicity after prophylactic brain irradiation in patients with small cell lung cancer: a study of event related potentials. J Neurooncol 50 (2000) 275-285
33. Phillips R.G., and LeDoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106 (1992) 274-285
34. Picton T.W., Hillyard S.A., Krausz H.I., and Galambos R. Human auditory evoked potentials. I. Evaluation of components. Electroencephalogr Clin Neurophysiol 36 (1974) 179-190
35. Potter D., Summerfelt A., Gold J., and Buchanan R.W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 32 (2006) 692-700
36. Reite M., Teale P., Zimmerman J., Davis K., and Whalen J. Source location of a 50 msec latency auditory evoked field component. Electroencephalogr Clin Neurophysiol 70 (1988) 490-498
37. Schagen S.B., Hamburger H.L., Muller M.J., Boogerd W., and van Dam F.S. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51 (2001) 159-165
38. Schagen S.B., van Dam F.S., Muller M.J., Boogerd W., Lindeboom J., and Bruning P.F. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85 (1999) 640-650
39. Seigers R., Schagen S.B., Beerling W., Boogerd W., van Tellingen O., van Dam F.S., Koolhaas J.M., and Buwalda B. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 186 (2008) 168-175
40. Siegel C., Waldo M., Mizner G., Adler L.E., and Freedman R. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch Gen Psychiatry 41 (1984) 607-612
41. Siegel S.J., Connolly P., Liang Y., Lenox R.H., Gur R.E., Bilker W.B., Kanes S.J., and Turetsky B.I. Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology 28 (2003) 675-682
42. Siegmund A., and Wotjak C.T. A mouse model of posttraumatic stress disorder that distinguishes between conditioned and sensitised fear. J Psychiatr Res 41 (2007) 848-860
43. Skinner R.D., Rasco L.M., Fitzgerald J., Karson C.N., Matthew M., Williams D.K., and Garcia-Rill E. Reduced sensory gating of the P1 potential in rape victims and combat veterans with posttraumatic stress disorder. Depress Anxiety 9 (1999) 122-130
44. Southwick S.M., Krystal J.H., Morgan C.A., Johnson D., Nagy L.M., Nicolaou A., Heninger G.R., and Charney D.S. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 50 (1993) 266-274
45. Stevens K.E., Freedman R., Collins A.C., Hall M., Leonard S., Marks M.J., and Rose G.M. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15 (1996) 152-162
46. Tannock I.F., Ahles T.A., Ganz P.A., and Van Dam F.S. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22 (2004) 2233-2239
47. Teo C., Rasco L., al-Mefty K., Skinner R.D., Boop F.A., and Garcia-Rill E. Decreased habituation of midlatency auditory evoked responses in Parkinson's disease. Mov Disord 12 (1997) 655-664
48. Umbricht D., Vyssotky D., Latanov A., Nitsch R., Brambilla R., D'Adamo P., and Lipp H.P. Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans. Brain Res 1019 (2004) 189-200
49. Winocur G., Vardy J., Binns M.A., Kerr L., and Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 85 (2006) 66-75